Study Stopped
Blood drawing protocol for RUH/ADARC. ADARC ceasing operations at RUH
Viral and Host Factors in the Transmission and Pathogenesis of HIV
1 other identifier
observational
600
1 country
2
Brief Summary
To study the collection of blood from individuals known to be at high risk for HIV-infection or who have been recently infected with HIV. The data collected are used for diagnostic, prognostic and management decisions as outlined by current HIV-1 Treatment Guidelines.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2000
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2000
CompletedFirst Submitted
Initial submission to the registry
September 20, 2005
CompletedFirst Posted
Study publicly available on registry
September 22, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2019
CompletedApril 10, 2019
April 1, 2019
18.7 years
September 20, 2005
April 8, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Participants are tested for HIV-1 RNA levels, the presence of antibodies to HIV antigens, and T cell subsets
first visit
Secondary Outcomes (1)
Data will be used for diagnostic, prognostic and management decisions as outlined by current HIV-1 Treatment
first visit
Study Arms (2)
high risk
Blood draw from individuals known to be or at high risk for HIV-infection
diagnosed
Blood draw f rom individuals diagnosed with HIV infection
Interventions
* T cell subset enumeration * Serologic reactivity with HIV antigens * Viral load assays by bDNA, PCR, or RT-PCR * Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR) * HIV-1 Resistance Testing
Eligibility Criteria
Subjects are either referred by primary health care providers, self-referred, or may be seeking enrollment in other ADARC clinical trials in the NYC area.
You may qualify if:
- recently infected with HIV-1 HIV-1 negative, and at high risk for infection
You may not qualify if:
- none
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Aaron Diamond AIDS Research Center (ADARC)
New York, New York, 10016, United States
Rockefeller University Hospital
New York, New York, 10021, United States
Related Links
Biospecimen
whole blood
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Martin M Markowitz, MD
Rockefeller University
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 20, 2005
First Posted
September 22, 2005
Study Start
July 1, 2000
Primary Completion
March 1, 2019
Study Completion
March 1, 2019
Last Updated
April 10, 2019
Record last verified: 2019-04
Data Sharing
- IPD Sharing
- Will not share